Patents Examined by Nita M. Minnifield
  • Patent number: 11382960
    Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: July 12, 2022
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler
  • Patent number: 11382973
    Abstract: The present invention provides an adjuvant that can cause immune activation or particularly T cell immune activation. The present invention provides an adjuvant that can cause particularly antigen-specific immune activation or particularly T cell immune activation.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 12, 2022
    Assignee: RIKEN
    Inventors: Shinichiro Fujii, Kanako Shimizu
  • Patent number: 11377484
    Abstract: The present invention relates to the field of bacterial Surface (S)-layer proteins, in particular to compounds capable of disrupting the bacterial S-Layer, specifically the S-Layer of Bacillus anthracis. More particularly, the invention provides for single domain antibodies for diagnosis and treatment of infection caused by pathogens with an S-Layer, in particular of Bacillus anthracis infection. The invention relates to S-Layer protein binding agents inhibiting bacterial growth and interrupting S-Layer assembly, useful in the treatment of bacterial infection, more specifically treatment of anthrax disease.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 5, 2022
    Assignees: VIB VZW, Vrij Universiteit Brussel
    Inventors: Han Remaut, Antonella Fioravanti
  • Patent number: 11376285
    Abstract: The invention relates to bacterial compositions useful in the treatment of cancer. In particular, the compositions can be used as a co-therapy with an immune checkpoint therapy. The invention also relates to methods for identifying a subject that will respond to therapy with an immune checkpoint inhibitor comprising determining the abundance of bacteria in a biological sample from said subject.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: July 5, 2022
    Assignee: Microbiotica Limited
    Inventors: Matthew Robinson, Trevor Lawley, Michael Romanos, Kevin Vervier, Simon Harris
  • Patent number: 11357821
    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 14, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Juergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
  • Patent number: 11357843
    Abstract: Disclosed are a bacteriologically-modified whole-cell tumor vaccine and a method of making the same. The method includes: lysing bacteria at logarithmic growth phase to obtain a bacterial lysate; mixing the bacterial lysate with an excessive amino compound solution to aminate the bacterial lysate in the presence of EDC; mixing the aminated bacterial lysate with the tumor cells for a certain period of time to produce bacteriologically-modified tumor cells; and inactivating the bacteriologically-modified tumor cells to produce the bacteriologically-modified whole-cell tumor vaccine. The bacteriologically-modified whole-cell tumor vaccine has been demonstrated to have desirable therapeutic effect in tumor model mice.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: June 14, 2022
    Assignee: Hainan Medical University
    Inventors: Guang-Hong Tan, Feng-Ying Huang, Liming Zhang, Zhuoxuan Lv, Ying-Ying Lin, Jie Jiang
  • Patent number: 11357838
    Abstract: A protease directed to a non-neuronal SNARE protein is described. The protease is produced by selective mutation of a botulinum neurotoxin light chain, and is characterized utilizing a reporting construct that includes all or part of the non-neuronal SNARE protein. Such a protease has utility in the treatment of diseases associated with hypersecretion, where the hypersecretion is mediated by a non-neuronal SNARE protein.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 14, 2022
    Assignee: BioMadison, Inc.
    Inventors: Francis Mark Dunning, Ward Tucker
  • Patent number: 11351232
    Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: June 7, 2022
    Assignee: REVANCE THERAPEUTICS, INC.
    Inventors: Stewart A. Thompson, Curtis L. Ruegg, Jacob M. Waugh
  • Patent number: 11333664
    Abstract: Methods for increasing specific uptake of a Botulinum neurotoxin are provided. Specific neurotoxin uptake by cells capable of being intoxicated by Botulinum neurotoxin is enhanced by increasing temperature from about 37° C. to up to about 41° C., as indicated by a decrease in the EC50 found for cells so treated. The effect requires the presence of both heavy and light chains of the Botulinum neurotoxin, and is serotype selective.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: May 17, 2022
    Assignee: BioMadison, Inc.
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 11332518
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: May 17, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • Patent number: 11324804
    Abstract: The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 10, 2022
    Assignee: Sepsia Therapeutics, S.L.
    Inventors: Francisco Lozano Soto, Mario Martinez Florensa
  • Patent number: 11318200
    Abstract: The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: May 3, 2022
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Duncan Mwangi, Joseph M. Bricker, Dennis L. Foss, Sharath K. Rai, Suman Mahan
  • Patent number: 11311496
    Abstract: Methods, compositions, and devices for enhancing transdermal delivery of large agents.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: April 26, 2022
    Assignee: Eirion Therapeutics, Inc.
    Inventor: Jonathan Edelson
  • Patent number: 11312965
    Abstract: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 26, 2022
    Assignee: TriSalus Life Sciences, Inc.
    Inventors: Dino Dina, Karen L. Fearon, Jason Marshall
  • Patent number: 11304996
    Abstract: Disclosed are methods of treating individuals with yeast-based immunotherapy who have been preselected as being sensitive to type I interferons, as well as methods for selecting individuals for treatment with yeast-based immunotherapeutic compositions and methods for enhancing or improving an individual's response to yeast-based immunotherapy, based on the individual's sensitivity to type 1 interferons (T1IFNs).
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: April 19, 2022
    Assignees: The Regents of the University of Colorado, a body corporate, GlobeImmune, Inc.
    Inventors: Donald Bellgrau, Thomas H. King
  • Patent number: 11286473
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 29, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • Patent number: 11285216
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: March 29, 2022
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 11279922
    Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: March 22, 2022
    Assignees: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical Center, National University Corporation Kagawa University
    Inventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
  • Patent number: 11278581
    Abstract: This invention provides for a method for improving the success rate of in vitro fertilization in women hosting abnormal vaginal microbiota. The method comprises the steps of: (i) selecting a woman suspected of hosting abnormal vaginal microbiota (AVM); (ii) administering to the woman a suitable antibiotic administered in an amount and duration effective to reduce the quantity of abnormal vaginal microbiota hosted by the woman; (iii) administering to the woman via vaginal administration an amount of Lactobacillus species in an amount sufficient to colonize the vaginal mucosa; and, (iv) transferring an embryo to the woman.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 22, 2022
    Assignee: Osel, Inc.
    Inventors: Thomas P. Parks, Peter Humaidan, Jørgen Skov Jensen, Niels Uldbjerg, Thor Haahr
  • Patent number: 11267879
    Abstract: Methods, devices, kits and compositions for detecting the presence or absence of hookworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of hookworm in a fecal sample from a mammal that may also be infected with one or more of roundworm, whipworm, and heartworm. Confirmation of the presence or absence of hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 8, 2022
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Jinming Geng, David Allen Elsemore